Last reviewed · How we verify
Lastacaft ®
Lastacaft is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye.
Lastacaft is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye. Used for Allergic conjunctivitis (itching associated with allergic conjunctivitis).
At a glance
| Generic name | Lastacaft ® |
|---|---|
| Sponsor | ORA, Inc. |
| Drug class | Selective H1-receptor antagonist (antihistamine) |
| Target | H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Allergy |
| Phase | FDA-approved |
Mechanism of action
Lastacaft (alcaftadine) works by competitively antagonizing H1 receptors on mast cells and other immune cells in ocular tissues, preventing histamine release and reducing allergic inflammation. This mechanism provides rapid relief of itching and other allergic symptoms in allergic conjunctivitis by inhibiting the cascade of allergic mediator release.
Approved indications
- Allergic conjunctivitis (itching associated with allergic conjunctivitis)
Common side effects
- Ocular irritation
- Headache
- Conjunctival hyperemia
Key clinical trials
- A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy (PHASE4)
- Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
- A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis (PHASE4)
- A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |